Related Experiment Video
Updated: Jul 17, 2026
07:25
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis
Marina Zafranskaya1, Patrick Oschmann, Rosel Engel
1Biochemisches Institut, Infektiologie, Justus-Liebig-Universität Giessen, Germany.
Immunology
|January 24, 2007
Summary
Interferon-beta (IFN-beta) therapy for multiple sclerosis (MS) reduces harmful autoreactive T cells. This treatment normalizes T cell responses to myelin oligodendrocyte glycoprotein (MOG), shifting them from pro-inflammatory to anti-inflammatory profiles.
Area of Science:
- Immunology
- Neuroimmunology
- T cell biology
Background:
- Interferon-beta (IFN-beta) is a key therapy for multiple sclerosis (MS).
- The precise immunomodulatory mechanisms of IFN-beta in MS remain incompletely understood.
- T cells, particularly CD4+ and CD8+ subsets, play a critical role in MS pathogenesis.
Purpose of the Study:
- To investigate the prevalence and functional capacity of T cells in MS patients.
- To assess the impact of IFN-beta therapy on T cell responses to myelin oligodendrocyte glycoprotein (MOG).
- To explore the potential of T cell analysis as a biomarker for successful MS immunotherapy.
Main Methods:
- Analysis of CD4+ and CD8+ T cell populations in healthy donors, untreated MS patients, and IFN-beta-treated MS patients.
- Assessment of T cell proliferation and cytokine profiles in response to myelin oligodendrocyte glycoprotein (MOG) in vitro.
- Correlation of peripheral T cell frequency with in vitro cellular responses.
Main Results:
- MS patients exhibited higher proportions of CD45RO+ memory T cells, which normalized with IFN-beta therapy.
- Untreated MS patients showed augmented T cell (CD4+ and CD8+) proliferative responses to MOG, which were reduced by IFN-beta treatment.
- IFN-beta therapy shifted T cell cytokine profiles from a type 1 (pro-inflammatory) to a type 2 (anti-inflammatory) phenotype.
Conclusions:
- IFN-beta therapy likely benefits MS patients by suppressing or depleting autoreactive, pro-inflammatory memory T cells.
- The observed shift towards a type 2 cytokine phenotype indicates a crucial immunomodulatory effect of IFN-beta.
- Monitoring T cell subsets and their reactivity to MOG could serve as a valuable tool for assessing IFN-beta immunotherapy efficacy in MS.
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.